New drug combo aims to keep blood cancer at bay after transplant
NCT ID NCT02619682
Summary
This study tested a two-drug maintenance therapy given after a patient's own stem cell transplant to help prevent multiple myeloma from coming back. Thirty patients received alternating cycles of two oral medications (ixazomib and lenalidomide) for up to two years. The main goal was to check the safety of this approach and see if it could extend the time patients remained cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.